Matthew Vessa joined Gilde in 2017 bringing over 20 years of experience in medtech, healthcare IT and diagnostics to the Boston office. Prior to joining Gilde, Matthew was VP of Operations for the Optum Analytics division of United Healthcare Group where he led a novel patient and clinician engagement business targeting high-value therapeutic markets. While leading the strategy and business development for the patient monitoring business at Philips, he co-founded Philips' genomics business venture focused on oncology and infectious disease. Matthew started his career in medtech with Becton Dickinson and C.R. Bard where his successes include supporting the acquisitions of Flowcardia, Clearstream, SenoRx and investments in Leutonix.
Matthew has a BS in biomedical engineering from the University of Rochester and an MBA in finance and marketing from Fordham University. He also served on the Board of Advisers for the University of Rochester School of Engineering.